Interview with Timothy Ko, CEO, Entheon
Entheon Biomedical and MPV Exploration have executed a definitive agreement, whereby MPV Exploration will acquire all the issued and outstanding shares of Entheon pursuant of a 3 cornered amalgamation.Click here to read the full press release
Entheon Biomedical is a biotechnology company committed to the legal development of safe & effective psychedelic medicines in order to provide patients with access to evidence-based treatments for addiction disorders.
There are many psychoactive plant medicines that indigenous cultures across the world have recognized for their medicinal properties. Modern science is now seeking to understand the neuro-chemical interactions and medicinal benefits of these substances in controlled, quantifiable laboratory settings in order to substantiate with scientific rigour, exactly how they interact with the brain to create their effects. Entheon Biomedical is focused on the development of proprietary medicines and treatments, based on psilocybin and its analogues, to address the public health concerns surrounding addiction and substance disorders.Current Market Our Solution
Various psychedelics such as DMT and 5-MeO-DMT demonstrate structural similarity to serotonin, binding to the 5-HT receptorsSubstances We Research
More and more clinical and academic research and trials into the effects of psychedelics on mental health are delivering promising results that may lead to future treatments for many conditions.